Literature DB >> 18594843

Accumulation, activation, and survival of neutrophils in ulcerative colitis: regulation by locally produced factors in the colon and impact of steroid treatment.

Maria Lampinen1, Per Sangfelt, Yesuf Taha, Marie Carlson.   

Abstract

BACKGROUND AND AIMS: Neutrophil granulocytes infiltrate the intestinal mucosa in active ulcerative colitis (UC), and may contribute to tissue damage and inflammation. The aim of this investigation was to study the importance of locally produced factors and the impact of steroid treatment on neutrophil functions in UC. PATIENTS AND METHODS: Intestinal perfusion fluids from 11 patients with active distal UC before and after seven and 28 days of treatment with prednisolone and from seven control patients were used in the study. Neutrophil migration towards perfusion fluid was measured in a microchemotaxis chamber. The effect of perfusion fluids on neutrophil activation was assessed as the surface expression of CD66b by flow cytometry. Neutrophil survival was evaluated by staining with propidium iodide, annexin V, and fluorescein di-acetate. We also assessed the viability of freshly isolated tissue neutrophils from rectal biopsy samples.
RESULTS: Perfusion fluids from untreated patients caused increased migration, activation, and survival of neutrophils. Perfusion fluids collected after treatment had no effect on neutrophil migration, but some of the activation and anti-apoptotic effects remained after 7 days. Anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) inhibited the anti-apoptotic effect of perfusion fluids. Rectal tissue neutrophils from patients with active proctitis had increased viability compared to patients with inactive proctitis and control subjects.
CONCLUSIONS: These data show that mediators in the colon of patients with active UC stimulate the migration, activation, and survival of neutrophils. The activities were partly neutralized by topical steroid treatment. We also identified GM-CSF as an anti-apoptotic factor for neutrophils in inflamed colon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594843     DOI: 10.1007/s00384-008-0509-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  29 in total

Review 1.  From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.

Authors:  Bruce E Sands
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

2.  Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

Authors:  E A Lobos; P Sharon; W F Stenson
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

3.  Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes.

Authors:  L C Meagher; J M Cousin; J R Seckl; C Haslett
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

4.  Neutrophil apoptosis is delayed in patients with inflammatory bowel disease.

Authors:  A E Brannigan; P R O'Connell; H Hurley; A O'Neill; H R Brady; J M Fitzpatrick; R W Watson
Journal:  Shock       Date:  2000-05       Impact factor: 3.454

Review 5.  The role of phagocytes in inflammatory bowel disease.

Authors:  A Hermanowicz; P R Gibson; D P Jewell
Journal:  Clin Sci (Lond)       Date:  1985-09       Impact factor: 6.124

6.  Glucocorticoid modulation of Bcl-2 family members A1 and Bak during delayed spontaneous apoptosis of bovine blood neutrophils.

Authors:  Sally A Madsen-Bouterse; Guilherme J M Rosa; Jeanne L Burton
Journal:  Endocrinology       Date:  2006-05-04       Impact factor: 4.736

7.  Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4.

Authors:  A T Cole; B J Pilkington; J McLaughlan; C Smith; M Balsitis; C J Hawkey
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

8.  Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases.

Authors:  James Jupp; Keith Hillier; Daniel H Elliott; David R Fine; Adrian C Bateman; Penny A Johnson; Angelica M Cazaly; John F Penrose; Anthony P Sampson
Journal:  Inflamm Bowel Dis       Date:  2007-05       Impact factor: 5.325

9.  Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis.

Authors:  Y Raab; B Gerdin; S Ahlstedt; R Hällgren
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

10.  The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids.

Authors:  Arne Egesten; Mette Eliasson; Anders I Olin; Jonas S Erjefält; Anders Bjartell; Per Sangfelt; Marie Carlson
Journal:  Int J Colorectal Dis       Date:  2007-08-17       Impact factor: 2.571

View more
  17 in total

1.  Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease.

Authors:  C B Larmonier; M T Midura-Kiela; R Ramalingam; D Laubitz; N Janikashvili; N Larmonier; F K Ghishan; P R Kiela
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

2.  The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.

Authors:  Rudolf Schicho; Mohammad Bashashati; Misha Bawa; Douglas McHugh; Dieter Saur; Huang-Ming Hu; Andreas Zimmer; Beat Lutz; Ken Mackie; Heather B Bradshaw; Donna-Marie McCafferty; Keith A Sharkey; Martin Storr
Journal:  Inflamm Bowel Dis       Date:  2010-11-15       Impact factor: 5.325

Review 3.  Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.

Authors:  Mel Pilar Espaillat; Richard R Kew; Lina M Obeid
Journal:  Adv Biol Regul       Date:  2016-11-14

4.  R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history.

Authors:  Fatih Eren; Mustafa Akkiprik; Ozlen Atuğ; Ozgür Sönmez; Gülgün Tahan; Filiz Ozdemir; Hülya Over Hamzaoğlu; Ciğdem Ataizi Celikel; Neşe Imeryüz; Erol Avşar; Ayşe Ozer
Journal:  Pathol Oncol Res       Date:  2010-03-23       Impact factor: 3.201

5.  Multivariate modeling identifies neutrophil- and Th17-related factors as differential serum biomarkers of chronic murine colitis.

Authors:  Megan E McBee; Yu Zeng; Nicola Parry; Cathryn R Nagler; Steven R Tannenbaum; David B Schauer
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

6.  Netrin-1 regulates colon-kidney cross talk through suppression of IL-6 function in a mouse model of DSS-colitis.

Authors:  Punithavathi Ranganathan; Calpurnia Jayakumar; Manicassamy Santhakumar; Ganesan Ramesh
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-27

7.  Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis.

Authors:  Angélica T Vieira; Caio T Fagundes; Ana Leticia Alessandri; Marina G M Castor; Rodrigo Guabiraba; Valdinéria O Borges; Kátia Daniella Silveira; Erica L M Vieira; Juliana L Gonçalves; Tarcilia A Silva; Maud Deruaz; Amanda E I Proudfoot; Lirlândia P Sousa; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

8.  CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation.

Authors:  Punithavathi Ranganathan; Calpurnia Jayakumar; Santhakumar Manicassamy; Ganesan Ramesh
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-28

9.  Orally administered extract from Prunella vulgaris attenuates spontaneous colitis in mdr1a(-/-) mice.

Authors:  Kelley Mk Haarberg; Meghan J Wymore Brand; Anne-Marie C Overstreet; Catherine C Hauck; Patricia A Murphy; Jesse M Hostetter; Amanda E Ramer-Tait; Michael J Wannemuehler
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 10.  Activators of SIRT1 in the kidney and protective effects of SIRT1 during acute kidney injury (AKI) (effect of SIRT1 activators on acute kidney injury).

Authors:  Alireza Raji-Amirhasani; Mohammad Khaksari; Fatemeh Darvishzadeh Mahani; Zahra Hajializadeh
Journal:  Clin Exp Nephrol       Date:  2021-03-29       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.